2 results match your criteria patientsresults upstaging

  • Page 1 of 1

Can we improve dental treatment outcomes in patients with high-risk factors?

Evid Based Dent 2021 01;22(1):42-43

Specialist Senior Registrar, Dental Services Department, Dubai Health Authority, Dubai, United Arab Emirates.

Aim The aim of the study was to identify best practice in relation to improving the periodontal conditions of patients and increasing the rate of treatment success, through the identification of risk factors and implementation of changes in lifestyle.Methods and materials The study used two search strategies to identify papers describing best practices and important lifestyle changes which improved periodontal conditions and treatment outcomes in patientsResults The study demonstrated that the two most important factors in terms of interventions to improve periodontal conditions and treatment outcomes were to improve the level of diabetes control and remove aggravating factors such as smoking.Conclusion Many studies have focused on improving treatment outcomes in patients with high-risk factors such as smoking and medical conditions. Read More

View Article and Full-Text PDF
January 2021

Interferon Alfa 2b for Ocular Surface Squamous Neoplasia: Factors Influencing the Treatment Response.

Semin Ophthalmol 2019 1;34(7-8):465-472. Epub 2019 Aug 1.

Mark Nathaniel Thadikonda and Vijayamma Nannepaga Centre for Eye Care Education and Ophthalmic Biophysics (AM), L V Prasad Eye Institute, Hyderabad, India.

Purpose: To study the factors influencing the response to treatment with interferon alfa 2b (IFN) in ocular surface squamous neoplasia (OSSN)Methods: Retrospective study of 91 patientsResults: The mean age at presentation of patients with OSSN was 58 years (median, 60 years; range, 21 to 83 years). The mean number of clock hours of conjunctiva/cornea/limbus involvement by the tumor was 6 (median, 6; range, 1 to 12). The mean duration of topical IFN was 3 months (median, 3 months; range, 1 to 6 months) and the mean number of subconjunctival injections of IFN was 2 (median, 2; range, 0 to 6), till complete tumor regression or initiation of alternate treatment. Read More

View Article and Full-Text PDF
January 2020
  • Page 1 of 1